Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: Comparative roles of β-adrenergic, 5-HT(1A), and 5-HT(1B) receptors

Neuropsychopharmacology

Volumn 21, Issue 2, 1999, Pages 268-284

  Gobert, Alain ^a   Millan, Mark J ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Antidepressant; Depression; Dialysis; Frontal cortex; Pindolol; Selective 5 HT Reuptake inhibitor

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; 3 [3 (2 DIMETHYLAMINOETHYL) 1H INDOL 5 YL] N (4 METHOXYBENZYL)ACRYLAMIDE; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; AUTORECEPTOR; BETA ADRENERGIC RECEPTOR; BETAXOLOL; DOPAMINE; DULOXETINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NORADRENALIN; PINDOLOL; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG RECEPTOR BINDING; FRONTAL CORTEX; MALE; MODULATION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; SUBCUTANEOUS DRUG ADMINISTRATION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; BETAXOLOL; DOPAMINE; FLUOXETINE; FRONTAL LOBE; GUINEA PIGS; HUMANS; MALE; MICRODIALYSIS; NOREPINEPHRINE; PINDOLOL; PIPERAZINES; PROPANOLAMINES; PYRIDINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0033013893     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00035-4     Document Type: Article

References (93)

1. 1Dβ receptor. Mol Pharmacol. 4:1992;1-7.
2. 1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram. Naunyn-Schmiedeberg's Arch Pharmacol. 353:1996;630-640.
3. 1A antagonists. Trends Neurosci. 19:1996;378-383.
4. 1B receptors. Neuropharmacology. 35:1996;213-222.
5. Berman R.M., Darnell A.M., Miller H.L., Anand A., Charney D.S. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression. A double-blind, placebo-controlled trial Am J Psychiatry. 154:1997;37-43.
6. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci. 15:1994;220-226.
7. Blier P., de Montigny C., Chaput Y. A role for serotonin system in the mechanism of action of antidepressant treatments. Preclinical evidence J Clin Psychiatry. 51:1990;14-20.
8. 1A receptors in augmenting antidepressant activity in the mouse forced swimming test. Psychopharmacology. 136:1998;226-234.
9. Bouthillier A., Blier P., de Montigny C. Flerobuterol, a β-adrenoceptor agonist, enhances serotonergic neurotransmission. An electrophysiological study in the rat brain Psychopharmacology. 103:1991;357-365.
10. Caldecott-Hazard S., Morgan D.G., Deleon-Jones F., Overstreet D.H., Janowsky D. Clinical and biochemical aspects of depressive disorders. II. Transmitter/receptor theories. Synapse. 9:1991;251-301.
11. 1A autoreceptor in vivo. Br J Pharmacol. 124:1998;206-212.
12. Conway P.G., Tejani-Butt S., Brunswick D.J. Interaction of beta adrenergic agonists and antagonists with brain beta adrenergic receptors in vivo. J Pharmacol Exp Ther. 241:1987;755-762.
13. 1A receptors in the rat brain. Br J Pharmacol. 123:1998;449-462.
14. 1B/D receptor antagonists. Neurosci Lett. 188:1995;41-44.
15. 1B/D antagonists with paroxetine on serotonin efflux in rat ventral lateral geniculate nucleus slices. Brain Res Bull. 43:1997;405-409.
16. 1A control of dorsal raphe cell firing and 5-HT release. NeuroReport. 9:1998;2535-2538.
17. 1A receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex. Eur J Pharmacol. 345:1998;41-46.
18. DeBattista C., Sofuoglu M., Schatzberg A.F. Serotonergic synergism. The risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs Biol Psychiatry. 44:1998;336-340.
19. Detke M.J., Reneric J., Lucki I. Pindolol boosts or blocks fluoxetine in the rat forced swimming test (FST) depending on the fluoxetine dose. Am Soc Neurosci. 22:1996;181.
20. 2 receptors. Microdialysis studies in the awake and anaesthetized rat Neuropharmacology. 33:1994;411-421.
21. Duncan G.E., Knapp D.J., Little K.Y., Breese G.R. Neuroanatomical specificity and dose dependence in the time course of imipramine-induced beta adrenergic receptor down-regulation in rat brain. J Pharmacol Exp Ther. 271:1994;1699-1704.
22. Engleman E.A., Perry K.W., Mayle D.A., Wong D.T. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of concious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology. 12:1995;287-295.
23. Fornal C.A., Martin F.J., Mendlin A., Bjorvatn B., Jacobs B.L. Pindolol increases extracellular serotonin levels in freely moving cats at doses which suppress serotonergic neuronal activity. Am Soc Neurosci. 24:1998;1363.
24. Frazer A. Antidepressants. J Clin Psychiatry. 58:1997;9-25.
25. Frishman W.H. Pindolol. A new β-adrenoceptor antagonist with partial agonist activity New Engl J Med. 308:1983;940-944.
26. 1A autoreceptors. Anxiety. 2:1996;149-152.
27. 1A receptor antagonist and an SSRI in vivo. effects on 5-HT cell firing and extracellular 5-HT Br J Pharmacol. 115:1995;1064-1070.
28. 1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]-2,3,6, 7-tetrahydro-spiro[furo [2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. J Med Chem. 41:1998;1218-1235.
29. Gobert A., Rivet J.-M., Cistarelli L., Millan M.J. Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J Neurochem. 68:1997;1326-1329. a.
30. 1B receptors with WAY 100,635 and GR 127,935. J Neurochem. 68:1997;1159-1163. b.
31. Gobert A., Rivet J.-M., Audinot V., Newman-Tancredi A., Cistarelli L., Millan M.J. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience. 84:1998;413-429.
32. 2-adrenergic receptors underlies its actions. Neuroscience, in press.
33. Goodwin G.M. Neuropsychological and neuroimaging evidence for the involvement of the frontal lobes in depression. J Psychopharmacol. 11:1997;115-122.
34. Grenhoff J., Nisell M., Ferré S., Aston-Jones G., Svensson T.H. Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J Neural Transm Gen Sect. 93:1993;11-25.
35. Haeusler G. Pharmacology of β-blockers. classical aspects and recent developments J Cardiovascular Pharmacol. 16:1990;S1-S9.
36. Herrero I., Sánchez-Prieto J. cAMP-dependent facilitation of glutamate release by β-adrenergic receptors in cerebrocortical nerve terminals. J Biol Chem. 271:1996;30554-30560.
37. 1A receptors or β-adrenoceptors, restrain the citalopram-induced increase in extracellular 5-hydroxytryptamine in vivo. Eur J Pharmacol. 316:1996;43-47.
38. 1A autoreceptor desensitization following chronic citalopram treatment, as determined by in vivo microdialysis. Neuropharmacology. 33:1994;331.
39. 1B autoreceptor blocking properties of the beta adrenoceptor antagonist (-)-penbutolol. J Pharmacol Exp Ther. 265:1993;707-712.
40. Hjorth S. Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine. Eur J Pharmacol. 303:1996;183-186.
41. Hoffman B.B., Lefkowitz R.J. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. Hardman J.G., Limbard L.E., Molinoff P.B., Ruddon R.W., Gilman A. The Pharmacological Basis of Therapeutics. 1996;199-248 McGraw-Hill, New York.
42. 1-adrenergic receptor mRNA and ligand binding by antidepressant treatments and norepinephrine depletion in rat frontal cortex. J Neurochem. 60:1993;1335-1343.
43. Hoyer D., Schoeffter P. 5-HT receptors. subtypes and second messengers J Receptor Res. 11:1991;197-214.
44. Ikegaya Y., Nakanishi K., Saito H., Abe K. Amygdala β-noradrenergic influence on hippocampal long-term potentiation in vivo. NeuroReport. 8:1997;3143-3146.
45. 1A receptor antagonists on citalopram-induced increase in extracellular serotonin in the frontal cortex, striatum and dorsal hippocampus. Neuropharmacology. 36:1997;467-473.
46. Jackson H.C., Needham A.M., Heal D.J. Pindolol potentiates the antidepressant-like effects of sertraline in the Porsolt test. J Psychopharmacol. 11:1997;A43.
47. 2-adrenoceptors as the mechanism whereby (-)-pindolol enhances DOI-induced hyperlocomotion in rats. Soc Neurosci Abstr. 23:1997;1216-1217.
48. Kelland M.D., Chiodo L.A. Serotoninergic modulation of midbrain dopamine systems. Ashby C.R. Jr. The Modulation of Dopaminergic Neurotransmission by Other Neurotransmitters. 1996;87-122 CRC Press, New York.
49. 1A autoreceptors of the dorsal and median raphe nuclei. Synapse. 25:1997;107-116.
50. 1A autoreceptors in rats treated with fluoxetine or paroxetine. Naunyn-Schmiedeb's Arch Pharmacol. 352:1995;141-148.
51. 1A receptors. WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535 Synapse. 30:1998;1-9.
52. Lejeune F., Gobert A., Rivet J.M., Melon C., Cistarelli L., Millan M.J. Pindolol increases dialysate levels of dopamine (DA) and noradrenaline (NAD), but not serotonin (5-HT), in the frontal cortex (FCX) of freely-moving rats. Am Soc Neurosci. 24:1998;861.
53. 1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in the rat. J Pharmacol Exp Ther. 280:1997;1241-1249.
54. Leonard B.E. The role of noradrenaline in depression. a review J Psychopharmacol. 11:1997;S39-S47.
55. 3 adrenergic receptors. Differential agonist activation of recombinant receptors in Chinese hamster ovary cells Mol Pharmacol. 42:1992;634-637.
56. Lucki I., Singh A., Kreiss D.S. Antidepressant-like behavioral effects of serotonin receptor agonists. Neurosci Biobehav Rev. 18:1994;85-95.
57. Maes M., Meltzer H.Y. The serotonin hypothesis of major depression. Bloom F.E., Kupfer D.J. Psychopharmacology. The Fourth Generation in Progress:1995;933-944 Raven, New York.
58. Malagié I., Trillat A.C., Douvier E., Anmella M.C., Dessalles M.C., Jacquot C., Gardier A.M. Regional differences in the effect of the combined treatment of WAY 100,635 and fluoxetine. An in vivo microdialysis study Naunyn-Schmiedeb's Arch Pharmacol. 354:1996;1-6.
59. Martin P., Soubrie P., Simon P. Shuttle-box deficits induced by inescapable shocks in rats. Reversal by the beta adrenoceptor stimulants clenbuterol and salbutamol Pharmacol Biochem Behav. 24:1986;177-181.
60. McAskill R., Mir S., Taylor D. Pindolol augmentation of antidepressant therapy. Br J Pharmacol. 173:1998;203-208.
61. Meltzer H.Y., Maes M. Effect of pindolol on hormone secretion and body temperature; partial agonist effects. J Neural Transm. 103:1996;77-88.
62. 2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity. J Pharmacol Exp Ther. 282:1997;132-147.
63. Millan M.J., Brocco M., Veiga S., Cistarelli L., Melon C., Gobert A. WAY 100,635 enhances both the "antidepressant" actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortex. Eur J Pharmacol. 341:1998;165-167. a.
64. 2C receptors tonically inhibit dopamine (DA) and noradrenaline (NAD), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology. 37:1998;953-955. b.
65. 1B receptors to G-protein coupling and function in corticolimbic structures. Neuropsychopharmacology, in press.
66. Misu Y., Kubo T. Presynaptic β-adrenoceptors. Med Res Rev. 6:1986;197-225.
67. 1A receptor antagonist, WAY-100635. Behav Pharmacol. 8:1997;585-606.
68. Murugaiah K.D., O'Donnell J.M. Facilitation of noradrenaline release from rat brain slices by β-adrenoceptors. Naunyn-Schmiedeb's Arch Pharmacol. 351:1995;483-490.
69. Nemeroff C.B. Augmentation strategies in patients with refractory depression. Depression Anxiety. 4:1997;169-181.
70. 1A receptors. Neuropsychopharmacology. 18:1998;395-398.
71. Nicholas A.P., Pieribone V.A., Hökfelt T. Cellular localization of messenger RNA for beta-1 and beta2 adrenergic receptors in rat brain. An in situ hybridization study Neuroscience. 56:1993;1023-1039.
72. O'Donnell J. Effect of the beta-2 adrenergic agonist zinterol on noradrenaline turnover. Res Commun Chem Pathol Pharmacol. 80:1993;113-116.
73. O'Donnell J. Pharmalogical characterization of the discriminative stimulus effects of clenbuterol in rats. Pharmacol Biochem Behav. 58:1997;813-818.
74. O'Donnell J., Frith S., Wilkins J. Involvement of beta-1 and beta-2 adrenergic receptors in the antidepressant-like effects of centrally administered isoproterenol. J Pharmacol Exp Ther. 271:1994;246-254.
75. Okada F., Tokumitsu Y. Is the β-down-regulation a prerequisite of the antidepressant activity? J Psychopharmacol. 8:1994;62-63.
76. Prisco S., Pagannone S., Esposito E. Serotonin-dopamine interaction in the ventral tegmental area. An electrophysiological study in vivo J Pharmacol Exp Ther. 271:1994;83-90.
77. Rivet J.-M., Gobert A., Cistarelli L., Melon C., Millan M.J. Antidepressants (ADs) differentially modify dialysate serotonin (5-HT), dopamine (DA) and noradrenaline (NAD) levels in rats. Am Soc Neurosci. 24:1998;1114.
78. 1A receptor antagonist in the dorsal raphe pathway. role of somatodendritic autoreceptors J Neurochem. 68:1997;2593-2603.
79. 1A receptors. In vivo microdialysis and electrophysiological studies in the rat brain Neuropsychopharmacology. 15:1996;349-360.
80. Rutter J.J., Gundlah C., Auerbach S.B. Systemic uptake inhibition decreases serotonin release via somatodendritic autoreceptor activation. Synapse. 20:1995;225-233.
81. Ruzicka B.B., Jhamandas K.H. Excitatory amino acid action on the release of brain neurotransmitters and neuromodulators. biochemical studies Prog Neurobiol. 40:1993;223-247.
82. 1A autoreceptor. J Neurosci Meth. 34:1990;83-90.
83. 1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. Br J Pharmacol. 121:1997;941-946.
84. Simiand J., Keane P.E., Guitard J., Langlois X., Gonalons N., Martin P., Bianchetti A., Le Fur G., Soubrié P. Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical β-adrenoceptors. Eur J Pharmacol. 219:1992;193-201.
85. 3-adrenoceptor mRNA in rat brain. Br J Pharmacol. 116:1995;2547-2548.
86. Tanda G., Carboni E., Frau R., Di Chiara G. Increase of extracellular dopamine in the prefrontal cortex. A trait of drugs with antidepressant potential? Psychopharmacology. 115:1994;285-288.
87. 3 receptors mediate fluoxetine but not desipramine-induced increase of extracellular dopamine in the prefrontal cortex. Psychopharmacology. 119:1995;15-19.
88. Thiessen B.Q., Wallace S.M., Blackburn J.L., Wilson T.W., Bergman U. Increased prescribing of antidepressants subsequent to β-blocker therapy. Arch Intern Med. 150:1990;2286-2290.
89. 1A receptor antagonists. Eur J Pharmacol. 357:1998;179-184.
90. 1B receptors of rat brain. Selectivity of β-adrenergic agents Jpn J Pharmacol. 52:1990;195-200.
91. 1A receptor ligands by drug discrimination. Eur J Pharmacol. 333:1997;113-122.
92. Zacharko R.M., Anisman H. Stressor-induced anhedonia in the mesocorticolimbic system. Neurosci Biobehav Rev. 15:1991;391-405.
93. Zohar J., Lere B., Belmaker R.H. Beta-2 adrenergic agonists for depression as a potential treatment. Zohar J., Belmaker R.H. Treating Resistant Depression. 1987;375-380 PMA Publishing, New York.